The changing model of insulin use in type 2 diabetes: Techniques, tactics for getting to goal

Postgraduate Medicine

Volumn 113, Issue 6, 2003, Pages 59-64

  Cooppan, R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LENTE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; CONFERENCE PAPER; DIET THERAPY; DRUG INDICATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; KINESIOTHERAPY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; UNITED STATES;

EID: 0038810285     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2003.06.1433     Document Type: Conference Paper

References (8)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988;37(6):667-87
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53
3. Clinical practice recommendations 2003. Diabetes Care 2003;26(Supp 1):S1-156
4. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to isletcell cytoplasm and glutamic acid decarboxylase for predication of insulin requirements in type 2 diabetes. Lancet 1997;350(9087):1288-93
5. Zimmet P, Turner R, McCarty D, et al. Crucial points at diagnosis: type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999;22(Suppl 2):B59-64
6. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99(20):2626-32
7. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345(19):1359-77
8. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997;20(4):597-606